Sergey Shevkoplyas,
Associate Professor, Biomedical Engineering,
University of Houston
Dr. Shevkoplyas is a biomedical engineer with core expertise in blood microfluidics. His primary research interests are the development and clinical translation of high-throughput microfluidic devices and single-cell analysis tools in the field of blood storage and transfusion medicine. An additional significant thrust of his research program is the development of enabling technology for low-cost, point-of-care diagnostics in resource-limited settings. Dr. Shevkoplyas is an Associate Professor in the Department of Biomedical Engineering at the University of Houston. He received his B.S. and M.S. degrees in Applied Mathematics & Physics from Moscow Institute of Physics & Technology, Russia in 2000, and his Ph.D. degree in Biomedical Engineering from Boston University in 2005. Dr. Shevkoplyas also completed a postdoctoral fellowship in Chemistry and Chemical Biology at Harvard University (2005 – 2008), and served on the faculty of Tulane University as an Assistant and Associate Professor of Biomedical Engineering (2008 – 2013). Dr. Shevkoplyas has authored 40 peer-reviewed articles, published two book chapters and is an inventor on 14 U.S. patents and patent applications. His research has been funded by the National Blood Foundation, the Bill & Melinda Gates Foundation, U.S. Army and the National Institutes of Health, including the recently awarded 2012 NIH Director's Transformative Research Award (T-R01).
Rapid, Low-Cost, Paper-Based Assay for Diagnosis of Sickle Cell Disease
Wednesday, 30 September 2015 at 14:30
Add to Calendar ▼2015-09-30 14:30:002015-09-30 15:30:00Europe/LondonRapid, Low-Cost, Paper-Based Assay for Diagnosis of Sickle Cell DiseasePoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Sickle cell disease (SCD) is one of the most common blood disorders causing life-long morbidity and premature mortality. More than 300,000 children are born each year with SCD worldwide, with nearly 75% of all affected births occurring in sub-Saharan Africa. A majority of children born with SCD in sub-Saharan Africa die before reaching the age of five. Most of these deaths could be prevented through simple and inexpensive prophylaxis if SCD is diagnosed early in life. Screening children for SCD with conventional laboratory methods is impractical in low-income developing countries because of the prohibitive cost and complexity of these methods. In this talk I will describe our recent work towards development and commercialization of a simple and inexpensive, paper-based test for point of care diagnostics of SCD in resource-limited settings.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World CongressPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-30 14:30:002015-09-30 15:30:00Europe/LondonRapid, Low-Cost, Paper-Based Assay for Diagnosis of Sickle Cell DiseasePoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
